Literature DB >> 20045435

Biochemical and biophysical characterisation of DBL1alpha1-varO, the rosetting domain of PfEMP1 from the VarO line of Plasmodium falciparum.

Alexandre Juillerat1, Sébastien Igonet, Inès Vigan-Womas, Micheline Guillotte, Stéphane Gangnard, Grazyna Faure, Bruno Baron, Bertrand Raynal, Odile Mercereau-Puijalon, Graham A Bentley.   

Abstract

Rosetting of erythrocytes infected with Plasmodium falciparum is frequently observed in children with severe malaria. This adhesion phenomenon has been linked to the DBL1alpha domain of P. falciparum erythrocyte membrane protein 1 (PfEMP1) in three laboratory clones: FCR3S1.2, IT4R29 and Palo Alto varO. Here, we compare the soluble recombinant NTS-DBL1alpha(1)-varO domain (NTS: N-terminal segment) obtained from E. coli, Pichia pastoris and baculovirus/insect cell expression systems. In each case, the presence of NTS was necessary for obtaining a soluble product. Successful expression in E. coli required maltose-binding protein as an N-terminal fusion partner. Each expression system produced an identical, correctly folded protein, as judged by biochemical and biophysical characterisations, and by the capacity to elicit antibodies that react with the surface of VarO-infected erythrocytes and disrupt VarO rosettes. Binding studies using surface plasmon resonance (SPR) techniques showed that NTS-DBL1alpha(1) produced in E. coli binds to heparin with micromolar affinity. IC(50) constants for other sulphated oligosaccharides were determined using SPR by measuring their competitive binding to the soluble protein in the presence of immobilized heparin. The affinity to NTS-DBL1alpha(1) was related to the degree of sulphation of the oligosaccharide, although the position of the sulphate groups on the sugar rings was also important. VarO rosettes could be disrupted by sulphated oligosaccharides with an efficacy that correlated with their binding affinity to recombinant NTS-DBL1alpha(1). Thus high yields of soluble NTS-DBL1alpha(1) with native conformation have been produced, opening novel perspectives for both structure-function studies and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20045435     DOI: 10.1016/j.molbiopara.2009.12.008

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  15 in total

Review 1.  Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies.

Authors:  Miloni Thakkar; Brijesh S
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

2.  Structure of a Plasmodium falciparum PfEMP1 rosetting domain reveals a role for the N-terminal segment in heparin-mediated rosette inhibition.

Authors:  Alexandre Juillerat; Anita Lewit-Bentley; Micheline Guillotte; Stéphane Gangnard; Audrey Hessel; Bruno Baron; Inès Vigan-Womas; Patrick England; Odile Mercereau-Puijalon; Graham A Bentley
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

3.  Insight into antigenic diversity of VAR2CSA-DBL5ε domain from multiple Plasmodium falciparum placental isolates.

Authors:  Sédami Gnidehou; Leon Jessen; Stéphane Gangnard; Caroline Ermont; Choukri Triqui; Mickael Quiviger; Juliette Guitard; Ole Lund; Philippe Deloron; Nicaise Tuikue Ndam
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

4.  The humoral response to Plasmodium falciparum VarO rosetting variant and its association with protection against malaria in Beninese children.

Authors:  Inès Vigan-Womas; Adjimon Lokossou; Micheline Guillotte; Alexandre Juillerat; Graham Bentley; André Garcia; Odile Mercereau-Puijalon; Florence Migot-Nabias
Journal:  Malar J       Date:  2010-10-05       Impact factor: 2.979

5.  Transfer of 4-hydroxynonenal from parasitized to non-parasitized erythrocytes in rosettes. Proposed role in severe malaria anemia.

Authors:  Sophie Uyoga; Oleksii A Skorokhod; Michael Opiyo; Emily N Orori; Thomas N Williams; Paolo Arese; Evelin Schwarzer
Journal:  Br J Haematol       Date:  2012-01-20       Impact factor: 6.998

6.  Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to Plasmodium falciparum.

Authors:  Ashfaq Ghumra; Pongsak Khunrae; Ricardo Ataide; Ahmed Raza; Stephen J Rogerson; Matthew K Higgins; J Alexandra Rowe
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

7.  Allelic diversity of the Plasmodium falciparum erythrocyte membrane protein 1 entails variant-specific red cell surface epitopes.

Authors:  Inès Vigan-Womas; Micheline Guillotte; Alexandre Juillerat; Cindy Vallieres; Anita Lewit-Bentley; Adama Tall; Laurence Baril; Graham A Bentley; Odile Mercereau-Puijalon
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

8.  Structural basis for the ABO blood-group dependence of Plasmodium falciparum rosetting.

Authors:  Inès Vigan-Womas; Micheline Guillotte; Alexandre Juillerat; Audrey Hessel; Bertrand Raynal; Patrick England; Jacques H Cohen; Olivier Bertrand; Thierry Peyrard; Graham A Bentley; Anita Lewit-Bentley; Odile Mercereau-Puijalon
Journal:  PLoS Pathog       Date:  2012-07-12       Impact factor: 6.823

9.  Analysis of antibody induction upon immunization with distinct NTS-DBL1α-domains of PfEMP1 from rosetting Plasmodium falciparum parasites.

Authors:  Davide Angeletti; Letusa Albrecht; Mats Wahlgren; Kirsten Moll
Journal:  Malar J       Date:  2013-01-24       Impact factor: 2.979

10.  Immunogenicity of the Plasmodium falciparum PfEMP1-VarO Adhesin: Induction of Surface-Reactive and Rosette-Disrupting Antibodies to VarO Infected Erythrocytes.

Authors:  Micheline Guillotte; Alexandre Juillerat; Sébastien Igonet; Audrey Hessel; Stéphane Petres; Elodie Crublet; Cécile Le Scanf; Anita Lewit-Bentley; Graham A Bentley; Inès Vigan-Womas; Odile Mercereau-Puijalon
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.